Ended · 07.05.2026
Supply shortage Denmark: Combigan 2+5 mg/ml øjendråber, opløsning (2care4 ApS) – Ended, 07.05.2026 · ENR Lægemiddelstyrelsen-ID 08ac9c6a-829d-4052-9c66-878f11d64152
Affected country: Denmark · Reported period: End of April 2026 – not specified · Active ingredient: nicht angegeben
Active ingredients
Notice context
A supply shortage has been recorded for Combigan 2+5 mg/ml øjendråber, opløsning (2care4 ApS) in Denmark. The stated reason is “Increased demand”. The notice concerns the active ingredient nicht angegeben and is not identified as hospital-relevant.
This information describes the reported supply status and is not medical or pharmaceutical treatment advice. Availability, alternatives and further measures must be assessed for each individual case by the responsible pharmaceutical market participants.
Official shortage notice for Denmark. Responsibility and update procedures follow the information supplied by the relevant authority.
Check the official notice list →Implications for procurement and the supply chain
The notice for Combigan 2+5 mg/ml øjendråber, opløsning (2care4 ApS) is a supply signal concerning nicht angegeben in Denmark. The published reason “Increased demand” determines which data should be verified first.
When demand rises, available stock, open orders, allocations, actual stock coverage and the confirmed replenishment date should be checked separately.
Once a lawful sourcing route is confirmed and buffer stock is required, our pharma warehouse in Cheb page explains receipt, stock control and picking.
Decision route for this supply case
- Confirm the notice, product identity, period and actual demand with the primary source and accountable market participants.
- Assess allocations, coverage, replenishment and a lawful product-specific buffer stock separately.
- Document release, stock status, GDP evidence, warehousing and transport process, and escalation responsibility.
Inter-Pharma can structure the B2B case, potential sourcing and warehousing routes, and operational implementation. Clinical decisions, regulatory permissibility, product release and actual availability remain with the accountable parties.
Request a structured supply review →Operational shortage resilience: GDP warehousing and pharmaceutical storage
For demand peaks, a lawful, product-specific safety or buffer stock for Combigan 2+5 mg/ml øjendråber, opløsning (2care4 ApS) can support operational coverage.
Inter-Pharma combines GDP-oriented pharmaceutical storage in Czechia with batch and expiry control, FEFO, stock status, picking and dispatch preparation in its own Cheb operation.
Storage at 15–25 °C or any 2–8 °C requirement is derived solely from the product specification and confirmed for the project.
Operational checks for this notice
- Match product identity using record Lægemiddelstyrelsen-ID 08ac9c6a-829d-4052-9c66-878f11d64152, active ingredient, strength, dosage form and pack.
- Confirm the reported status and the period Ende April 2026 to nicht angegeben with the primary source and potential suppliers.
- Document demand, stock coverage, open orders and lawful alternative or sourcing routes for the specific case.
- Clarify temperature, batch, expiry, stock status, recipient authorisation and GDP evidence before cross-border supply.
Relevant services and specialist pages
The following B2B topics are particularly relevant when handling a shortage involving Combigan 2+5 mg/ml øjendråber, opløsning (2care4 ApS):